Indication
Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
- persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication
- house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment
Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
Medicine details
- Medicine name:
- D. pteronyssinus & D. farinae allergen extracts (Acarizax)
- SMC ID:
- SMC2885
- Pharmaceutical company
- ALK-Abello Ltd
- BNF chapter
- Immunological products and vaccines
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC